[Correspondence] Anti-PD-1 antibody treatment for melanoma – Authors' reply

We reported multiple ways to assess the subsequent response of TBP and did not endorse one method over another.1 Although we reported that 19% (95 of 500) of assessable patients in the TBP cohort had subsequent decreases in target lesion tumour burden of 30% or more, we also reported that this population represented only 4% of the total treated population of 2624 patients.

Source: The Lancet Oncology - April 26, 2018 Category: Cancer & Oncology Authors: Julia A Beaver, Patricia Keegan, Steven Lemery, Richard Pazdur, Marc R Theoret Tags: Correspondence Source Type: research